Issue Areas

Drug Policy

Prescription drug prices continue to rise, threatening to make vital therapies unaffordable for many patients.

Learn more

As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is critical for policymakers to understand the root causes and potential solutions.

Focus areas
High Cost Of Prescription Drugs: Concept Prescription Bottles With Gavel
Fostering Competitive Markets
Ballpoint Pen Lying On Medical Prescription Near Phonendoscope In Doctors Office. Illegal Prescription Of Drugs Concept
High-Value Therapies for Patients
Featured content
Syringes With Needed
Biosimilars at Kaiser Permanente: Lessons in successfully reducing spending on prescription drugs
Publications from PORTAL
A Man Handing A Prescription To A Pharmacists
Restoring Provider Confidence In FDA-Approved Drugs
A Pharmacist Fulfilling A Prescription
Evolving nature of evidence required by FDA to approve new drugs
Ballpoint Pen Lying On Medical Prescription Near Phonendoscope In Doctors Office. Illegal Prescription Of Drugs Concept
Drug policy 101: Kaiser Permanente’s Approach to Pharmaceutical Detailing
Prescription White Pills
Building a bigger table for a more equitable drug development system
The Medicaid Drug Rebate Program and the impact of “best price” rules
Drug policy 101: Pharmaceutical marketing tactics
The promise — and challenges — of gene therapy
Prescription
Determining drug value: Let’s start with the evidence
Drug policy 101: Breaking down different types of drug products
Capitol Dome
How to save the patent system in 3 easy steps
It’s time to change drug companies’ harmful marketing practices
A Man Handing A Prescription To A Pharmacists
The price Is wrong: Why we need to curb prices on biologics to protect patients
High Cost Of Prescription Drugs: Concept Prescription Bottles With Gavel
A deeper dive: Recommendations for strengthening the FDA’s REMS program to protect patients
The US Capitol Dome, Interior, Washington DC
Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)
Drug policy 101
Drug policy 101: Kaiser Permanente’s Approach to Pharmaceutical Detailing
Drug policy 101: Pharmaceutical marketing tactics
Drug policy 101: Breaking down different types of drug products
Drug policy 101: The state of the pharmaceutical evidence base
Drug policy 101: Drug patents
Drug policy 101: Biosimilars
Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)
Drug Policy 101: Pay-for-delay
Events
Pills
Building Racial Equity into the Drug Development System: Clinical Trials, Access, and Affordability
Pills
Building Racial Equity into the Drug Development System
Unpacking Drug Value Forum Banner Photo Of Prescription Drugs Arranged In A Dollar Sign
Unpacking Drug Value
Kaiser Permananete Institute For Total Health Forums
Addressing High Drug Pricing